Oral fludarabine has significant activity in patients with previously untreated chronic lymphocytic leukemia, and leads to increased STAT1 levels in vivo-Reference-Cited by-同舟云学术

Oral fludarabine has significant activity in patients with previously untreated chronic lymphocytic leukemia, and leads to increased STAT1 levels in vivo

Published:2004-02 Issue:2 Volume:28 Page:139-147
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Friedberg Jonathan W,Dong Danielle A,Li Sigui,Kim Helen,Stephans Katherine,Noonan Kimberly,Neuberg Donna,Gribben John G,Fisher David C,Freedman Arnold S,Takvorian Tak,Jurgens Ray,Battle Traci E,Frank David A

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference34 articles.

1. Incidence of leukemia in Olmsted County, Minnesota, 1975 through 1989;Call;Mayo. Clin. Proc.,1994

2. Chronic lymphocytic leukemia incidence is substantially higher than estimated from tumor registry data;Zent;Cancer,2001

3. Chronic lymphocytic leukemia;Kipps;Curr. Opin. Hematol.,2000

4. Fludarabine phosphate: a synthetic purine antimetabolite with significant activity against lymphoid malignancies;Chun;J. Clin. Oncol.,1991

5. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients;Leporrier;Blood,2001

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Deciphering the metabolic basis and molecular circuitry of the Warburg effect in lymphoma;2023-11-21

2. Differential roles of type I interferon signaling in tumor versus host cells in experimental glioma models;Translational Oncology;2023-02

3. The Pro-Survival Oct4/Stat1/Mcl-1 Axis Is Associated with Poor Prognosis in Lung Adenocarcinoma Patients;Cells;2021-10-03

4. Drug-repositioning screening identified fludarabine and risedronic acid as potential therapeutic compounds for malignant pleural mesothelioma;Investigational New Drugs;2020-12-09

5. In silico simulations of STAT1 and STAT3 inhibitors predict SH2 domain cross-binding specificity;European Journal of Pharmacology;2013-11